SML1281
Capecitabine Ready Made Solution
10 mg/mL in DMSO
别名:
5′-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
InChI key
GAGWJHPBXLXJQN-UORFTKCHSA-N
InChI
1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
form
DMSO solution
concentration
10 mg/mL in DMSO
shipped in
dry ice
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Capecitabine is an anti-cancer drug, a prodrug of doxifluridine, metabolized to 5-fluorouracil at the tumor site.
Capecitabine is a fluoropyrimidine carbamate that undergoes preferential conversion to 5-fluorouracil in cancerous tissues.
Capecitabine is an anti-cancer drug, a prodrug of doxifluridine, metabolized to 5-fluorouracil at the tumor site. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5′-Deoxy-5-fluorocytidine (5′-DFCR) and 5′-Deoxy-5-fluorouridine (5′-DFUR), to form 5-fluorouracil.
signalword
Danger
hcodes
Hazard Classifications
Carc. 1B - Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
188.6 °F
flash_point_c
87 °C
法规信息
新产品
此项目有
J Schüller et al.
Cancer chemotherapy and pharmacology, 45(4), 291-297 (2001-02-07)
[corrected] Capecitabine (Xeloda) is a novel fluoropyrimidine carbamate rationally designed to generate 5-fluorouracil (5-FU) preferentially in tumors. The purpose of this study was to demonstrate the preferential activation of capecitabine, after oral administration, in tumor in colorectal cancer patients, by
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持